BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18234433)

  • 1. Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group.
    Eich HT; Engenhart-Cabillic R; Hansemann K; Lukas P; Schneeweiss A; Seegenschmiedt H; Skripnitchenko R; Staar S; Willich N; Müller RP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1419-24. PubMed ID: 18234433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
    Eich HT; Müller RP; Ansén S; Josting A; Engert A; Hansemann K; Pfistner B; Wolf J; Willich N; Diehl V
    Rontgenpraxis; 2003; 55(3):114-24. PubMed ID: 15119314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The radiotherapy reference panel--experiences and results of the German Hodgkin Study Group (GHSG).
    Eich HT; Müller RP
    Eur J Haematol Suppl; 2005 Jul; (66):98-105. PubMed ID: 16007876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies.
    Eich HT; Müller RP; Schneeweiss A; Hansemann K; Semrau R; Willich N; Rübe C; Sehlen S; Hinkelbein M; Diehl V
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):805-8. PubMed ID: 14967437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group.
    Kriz J; Bangard C; Haverkamp U; Bongartz R; Baues C; Engert A; Mueller RP; Eich HT
    Strahlenther Onkol; 2012 Aug; 188(8):660-5. PubMed ID: 22692351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfart K; Lukas P; Plütschow A; Schmidberger H; Staar S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):109-115. PubMed ID: 27596217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience with the quality assurance program of radiation therapy on behalf of Japan Radiation Oncology Group (JAROG).
    Isobe K; Kagami Y; Higuchi K; Kodaira T; Hasegawa M; Shikama N; Nakazawa M; Fukuda I; Nihei K; Ito K; Teshima T; Oguchi M;
    Jpn J Clin Oncol; 2007 Feb; 37(2):135-9. PubMed ID: 17255160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
    Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of radiation therapy within the German Hodgkin Study Group trials.
    Eich HT; Kriz J; Müller RP
    J Natl Compr Canc Netw; 2011 Sep; 9(9):1073-80. PubMed ID: 21917628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfarth K; Lukas P; Schmidberger H; Marnitz-Schulze S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):100-108. PubMed ID: 27678010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACR Appropriateness Criteria on Hodgkin's lymphoma: favorable prognosis stage I and II.
    Das P; Ng A; Constine LS; Hodgson DC; Mendenhall NP; Morris DE; Yunes MJ; Chauvenet AR; Hudson MM; Winter JN
    J Am Coll Radiol; 2008 Oct; 5(10):1054-66. PubMed ID: 18812149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience.
    Olcese F; Clavio M; Rossi E; Spriano M; Ballerini F; Canepa L; Pierri I; Aquino S; Varaldo R; Manna A; Secondo V; Racchi O; Balleari E; Orcioni GF; Carella AM; Ghio R; Gobbi M
    Ann Hematol; 2009 Sep; 88(9):855-61. PubMed ID: 19189105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)].
    Roth SL; Dühmke E; Kirschner H; Willich N; Müller RP; Bleher A; Pfreundschuh M; Löffler M; Diehl V
    Strahlenther Onkol; 1990 Sep; 166(9):584-7. PubMed ID: 2120784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin's lymphoma.
    Haas RL; Girinsky T; Aleman BM; Henry-Amar M; de Boer JP; de Jong D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1199-202. PubMed ID: 19131186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicities.
    Goda JS; Tsang RW
    Hematol Oncol; 2009 Sep; 27(3):115-22. PubMed ID: 19274613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study.
    Micke O; Seegenschmiedt MH;
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):882-91. PubMed ID: 15708271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: a systematic review.
    Bekelman JE; Yahalom J
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):492-8. PubMed ID: 18804334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.